Dordaviprone 125 MG Oral Capsule — RxCUI 2721199
RxNorm drug concept · Semantic clinical drug
RxCUI 2721199
Semantic clinical drug · SCD
● Current RxNorm concept 1 FDA product
1 package NDC
Snapshot Jul 14, 2026
What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.
🗂️ Key Facts
RxCUI2721199
Official nameDordaviprone 125 MG Oral Capsule
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known asdordaviprone 125 MG (equivalent to dordaviprone hydrochloride 148.8 MG) Oral Capsule
FDA products mapped1
Package NDCs mapped1
Reported Medicaid activity (SDUD)35 prescriptions · 2 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026
🕸️ Concept Web — How Dordaviprone 125 MG Oral Capsule Connects
One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept
Dordaviprone 125 MG Oral Capsule
RxCUI 2721199 Semantic clinical drug · SCD
Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.
-
Ingredients 1
The active substance itself — no strength, form, or brand attached yet.
-
Dordaviprone
2721194IN
-
Dordaviprone
-
Brand names 1
The same medicine's trade names. A brand name alone says nothing about strength or form.
-
Modeyso
2721200BN
-
Modeyso
-
Dose forms 9
The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
-
Dordaviprone Oral Capsule
2721198SCDF -
Dordaviprone Oral Product
2721196SCDG -
Dordaviprone Pill
2721197SCDG -
Dordaviprone Oral Capsule [Modeyso]
2721204SBDF -
Modeyso Oral Product
2721202SBDG -
Modeyso Pill
2721203SBDG -
Oral Capsule
316965DF -
Oral Product
1151131DFG - +1 more in this family
-
Dordaviprone Oral Capsule
-
Clinical & branded drugs 3
Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
-
Dordaviprone 125 MG
2721195SCDC -
Dordaviprone 125 MG Oral Capsule [Modeyso]
2721205SBD -
Dordaviprone 125 MG [Modeyso]
2721201SBDC
-
Dordaviprone 125 MG
Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.
🔀 Generic ⇄ Brand Crosswalk
The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.
Generic (Clinical) Concepts
-
Dordaviprone 125 MG
SCDC · 2721195 -
Dordaviprone Oral Capsule
SCDF · 2721198 -
Dordaviprone Oral Product
SCDG · 2721196 -
Dordaviprone Pill
SCDG · 2721197
Brand-Name Concepts
-
Dordaviprone 125 MG Oral Capsule [Modeyso]
SBD · 2721205 -
Dordaviprone 125 MG [Modeyso]
SBDC · 2721201 -
Dordaviprone Oral Capsule [Modeyso]
SBDF · 2721204 -
Modeyso Oral Product
SBDG · 2721202 -
Modeyso Pill
SBDG · 2721203 -
Modeyso
BN · 2721200
📦 FDA Products & Package NDCs
1 product · 1 package NDC
1 package NDC map to RxCUI 2721199 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
| Package NDC | Package | Brand / generic name | Labeler | Marketing start |
|---|---|---|---|---|
| 68727-0250-01 | 1 BOTTLE in 1 CARTON (68727-250-01) / 10 CAPSULE in 1 BOTTL... | MODEYSO | Jazz Pharmaceuticals, Inc. | 2025-08-06 |
Observed labelers:
Jazz Pharmaceuticals, Inc. (1)
— this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.
🗃️ Sources & Limits
Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
- A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
- Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
- Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
- Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.